Abstracts tagged "Sjogren’s syndrome and rheumatoid arthritis (RA)"

Abstract Number: 986 • 2014 ACR/ARHP Annual Meeting
Integrated Comprehensive Analysis of Immune Cell Subsets and Serum Protein Profile Identifies the Role of Pre-Germinal Center B Cells in Sjogren’s Syndrome Pathogenesis
Yoshiaki Kassai¹, Katsuya Suzuki², Rimpei Morita³, Maiko Takiguchi¹, Rina Kurisu¹, Takahiro Miyazaki¹, Akihiko Yoshimura³ and Tsutomu Takeuchi², ¹Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Whole blood flow cytometric analysis and serum protein profiling were commonly utilized to characterize disease-specific alterations in a wide variety of autoimmune diseases. However,…
Abstract Number: 852 • 2013 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosous and Primary Sjogren’s Syndrome May Display Joint Erosions On MRI As Well As Healthy Control, But Cannot Be Considered As Erosive Disease Such As Rheumatoid Arthritis: : An MRI Observational Study Of 90 Subjects
Frédérique Gandjbakhch¹, Violaine Foltz², Jérôme Renoux³, Nahalie Cozic⁴, Nathalie Costedoat-Chalumeau⁵, Damien Sene⁶, Guillaume Mercy⁷, Zahir Amoura⁸, Jean-Charles Piette⁹, Nathalie Morel¹⁰, Pierre Bourgeois¹¹ and Bruno Fautrel¹², ¹Department of Rheumatology, APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, ²APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, ³Radiology, Pitie-Salpetriere Hospital, Paris, France, ⁴APHP, Pitie Salpetriere Hospital, department of statistics, Paris, France, ⁵Internal Medicine, Hopital Cochin, Paris, France, ⁶Internal Medicine, Hopital Lariboisière, Paris, France, ⁷APHP, Pitie-Salpétrière Hospital, paris, France, ⁸Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁹Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ¹⁰Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ¹¹Rheumatology, APHP,Pitie-Salpetriere Hospital, Paris 6, Paris, France, ¹²Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: Recent studies tend to demonstrate presence of MRI erosion in Systemic Lupus Erythematosous (SLE) and primary Sjogren’s syndrome (pSS). The objective of this study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].